Genspeed Biotech
Genspeed Biotech is an Austrian in-vitro diagnostics company that develops and commercializes the GENSPEED xPOC platform, a CE-IVD/IVDR-certified multiplex point-of-care system delivering lab-quality biomarker results from a single drop of capillary blood in 15–20 minutes for physicians, pharmacies, dental offices, and OEM test manufacturers across Europe.
- Company typePrivate
- Founded2016
- HeadquartersRainbach, Austria
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genspeed Biotech does
Genspeed Biotech GmbH is an Austrian in vitro diagnostics company founded in 2016 as a spin-off from Greiner Bio-One, headquartered in Rainbach, Austria. The company has built and commercializes the GENSPEED xPOC platform — a patented point-of-care system that integrates microfluidics, miniaturized chemiluminescence-based optical detection, and cartridge-based automation to quantify up to eight biomarkers simultaneously from 20–50 µl of capillary blood in 15–20 minutes, delivering results comparable in quality to standard laboratory ELISA methods.
Genspeed Biotech firmographics
Firmographics- Name
- Genspeed Biotech
- Legal name
- Genspeed Biotech GmbH
- Website
- https://genspeed-biotech.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Genspeed Biotech is an Austrian in-vitro diagnostics company that develops and commercializes the GENSPEED xPOC platform, a CE-IVD/IVDR-certified multiplex point-of-care system delivering lab-quality biomarker results from a single drop of capillary blood in 15–20 minutes for physicians, pharmacies, dental offices, and OEM test manufacturers across Europe.
- Ownership category
- akta.pro rank
Genspeed Biotech industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Genspeed Biotech is headquartered
LocationHeadquarters
- HQ city
- Rainbach
- HQ country
- Austria
- HQ region
- Europe
Offices1 record
Markets served
Genspeed Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Diagnostic Test Kits Sales: Sale of branded IVD-CE/IVDR certified rapid diagnostic test kits including Vitamin D xPOC, COVID-19 IgG xPOC, FSME IgG xPOC, and PerioPOC Pro for dental applications. Tests are sold through direct sales, sales partners, and at public health events.
- OEM Platform Licensing: Licensing of the CE-IVD certified GENSPEED technology platform to test manufacturers for developing their own multiplex rapid tests. Partners can leverage the platform to create custom assays for specific biomarkers or applications.
- GENSPEED R2 Instrument Sales: Sale of the GENSPEED R2 test instrument and associated software to healthcare providers (physicians, pharmacies, dental offices) who then purchase consumable test kits.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | No public pricing available - Quote-based model |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Genspeed Biotech product offering
Product offeringCore offering
Genspeed Biotech develops, manufactures and distributes the CE-IVD and IVDR-certified GENSPEED point-of-care diagnostic platform, combining microfluidics, miniaturized chemiluminescence-based optical detection and automation in a compact cartridge-based system. The platform quantifies up to 8 biomarkers simultaneously from 20-50 µl of capillary blood in 15-20 minutes, and is delivered as branded test kits (Vitamin D xPOC, COVID-19 IgG xPOC, FSME IgG xPOC, PerioPOC Pro), the GENSPEED R2 instrument with proprietary Immuno Report Software, and as an OEM technology platform licensed to third-party test manufacturers.
Product overview
Genspeed Biotech GmbH offers the GENSPEED technology platform as its core product — a CE-IVD and IVDR-certified multiplexed rapid testing system. The platform consists of the GENSPEED R2 automated instrument, xPOC test cartridges, and the GENSPEED Immuno Report Software. The product portfolio comprises four main diagnostic tests: Vitamin D xPOC (quantitative Vitamin D detection, IVDR certified 2024), FSME IgG xPOC (TBE antibody testing, launched 2022), COVID-19 IgG xPOC (SARS-CoV-2 antibody testing, launched 2020), and PerioPOC Pro (dental periodontitis pathogen detection). All protein-based tests share the same xPOC cartridge technology and deliver results in 15–20 minutes from a single drop of capillary blood. The company also offers an OEM platform for third-party test manufacturers, and a development collaboration with Charité Berlin on a three-biomarker PJI test.
Differentiator
Problem solved
Functional benefit
Brands
- PerioPOC Pro: A dental diagnostic tool enabling rapid differential diagnosis, therapy decisions, and therapy monitoring for periodontitis treatment directly in dental practices
- xPOC
- GENSPEED Immuno Assays
- GENSPEED R2
- GENSPEED OEM
Products and services
- Vitamin D xPOC Test In vitro diagnostic test for the quantitative detection of 25(OH) Vitamin D3 from human capillary blood (50 µl) or venous blood (serum) in approximately 20 minutes; measurement range 12-100 ng/mL; IVDR certified under EU 2017/746. Intended for doctors' offices and pharmacies.
- FSME IgG xPOC Test Antibody test for the detection of IgG antibodies against Tick-Borne Encephalitis (TBE/FSME) virus from fingertip blood in 20 minutes; sensitivity 99.3%, specificity 100%; approved for capillary blood only; used to assess vaccine-induced protection.
- COVID-19 IgG xPOC Test Serological antibody test detecting IgG antibodies against three SARS-CoV-2 antigens from a drop of fingertip blood (20 µl) in 15-20 minutes; sensitivity 100%, specificity 93% vs. six laboratory ELISA methods.
- PerioPOC Pro Point-of-care diagnostic tool for dentists enabling rapid differential diagnosis, therapy decisions and therapy monitoring in the treatment of periodontitis through direct detection of periodontitis pathogens in dental offices.
- GENSPEED R2 Device The compact, fully automated GENSPEED R2 test instrument that reads GENSPEED xPOC test chips using chemiluminescence-based optical detection and operates with the GENSPEED Immuno Report Software on a connected laptop/tablet. Sold to physicians, pharmacies and dental offices who then purchase consumable test kits.
- GENSPEED OEM Platform OEM licensing of the CE-IVD and IVDR certified GENSPEED multiplex rapid testing platform to in vitro diagnostics manufacturers, enabling them to develop their own multiplexed assays for specific biomarkers or applications without building the underlying platform from scratch.
- GENSPEED Immuno Report Software Proprietary desktop software that controls the GENSPEED R2 device, manages patient data, generates PDF laboratory reports automatically, supports batch registration and calibration management, and enables LIMS integration for bidirectional data transfer.
Quantifiable outcome
- COVID-19 IgG xPOC achieved 100% sensitivity and 93% specificity compared to 6 laboratory ELISA methods (Journal of Clinical Virology)
- +3 more outcomes
Companies that use Genspeed Biotech
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Genspeed Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Genspeed Biotech partnerships and signals
Strategic signalScale indicators4 records
Recent moves7 records
Expansion highlights6 records
Genspeed Biotech competitors and assessment
Company assessmentDirect peers
- Eurolyser Diagnostica: Austrian POC diagnostics manufacturer offering compact readers and reagents for clinical chemistry, immunology, and infectious disease. Comparable as a regional Austrian rival selling branded IVD rapid tests and instruments through channel partners across Europe.
- EKF Diagnostics: UK-headquartered POC diagnostics specialist with hemoglobin, HbA1c, lactate, and COVID-19 rapid tests distributed in Europe and the US. Comparable as a small-cap POC diagnostics platform competitor with branded kits plus OEM/private-label activity.
- Abionic: Swiss POC IVD developer using nanofluidic technology for rapid multiplex blood-based biomarker quantification. Comparable as a small European POC platform company with proprietary detection chemistry and a focus on rapid point-of-care biomarker tests for clinicians and pharmacies.
- Response Biomedical: Canadian POC immunochromatographic company (RAMP platform) focused on cardiac, infectious disease, and biodefense markers. Comparable as a small-cap multiplex rapid IVD player with OEM and branded distribution in Europe.
Broad incumbents
- QuidelOrtho: Large US-based rapid diagnostics company with Triage, Sofia, and QuickVue product lines spanning immunoassays and lateral flow. Comparable as a broad incumbent in rapid POC diagnostics with overlapping indications (infectious disease, cardiac, women's health) and IVDR-compliant European operations.
- Siemens Healthineers POC: Operates the epoc blood gas and DCA Vantage systems, and broader IVD menu. Comparable as a broad incumbent offering POC immunoassay and chemistry testing to physicians and pharmacies in Europe under IVDR.
- Sekisui Diagnostics: Provider of clinical chemistry and immunoassay systems including Acucy and OSOM rapid tests. Comparable as a broad incumbent in rapid IVDs with POC and OEM offerings overlapping Genspeed's IVDR-licensed test menu approach.
- Abbott Point of Care: Division of Abbott operating the i-STAT and Piccolo POC platforms used in hospitals, physicians' offices, and pharmacies. Comparable as an established POC platform incumbent against which Genspeed's R2 competes for rapid blood-based testing menus and European IVD channels.
Others
- Meso Scale Diagnostics: US-based manufacturer of multiplex electrochemiluminescence immunoassay platforms (Meso QuickPlex, U-Plex). Comparable as a multiplex immunoassay technology platform whose instrument-plus-assay model is structurally similar to Genspeed's R2-plus-xPOC cartridge model, even though it targets research/lab settings rather than POC.
Emerging players
- QuantuMDx: UK-based developer of rapid molecular POC tests (Q-POC) for infectious disease. Comparable as an emerging player using a proprietary miniaturized detection platform to deliver laboratory-grade results in minutes at the point of care.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genspeed Biotech social profiles
Digital presenceGenspeed Biotech compliance and trust
Trust signalCompliance4 records
Genspeed Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genspeed Biotech leadership team
Management profileNumber of profiles
Profiles2 records
Genspeed Biotech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genspeed Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genspeed Biotech
What does Genspeed Biotech do?
Genspeed Biotech develops, manufactures and distributes the CE-IVD and IVDR-certified GENSPEED point-of-care diagnostic platform, combining microfluidics, miniaturized chemiluminescence-based optical detection and automation in a compact cartridge-based system. The platform quantifies up to 8 biomarkers simultaneously from 20-50 µl of capillary blood in 15-20 minutes, and is delivered as branded test kits (Vitamin D xPOC, COVID-19 IgG xPOC, FSME IgG xPOC, PerioPOC Pro), the GENSPEED R2 instrument with proprietary Immuno Report Software, and as an OEM technology platform licensed to third-party test manufacturers.
Is Genspeed Biotech a public or private company?
Genspeed Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Genspeed Biotech founded?
Genspeed Biotech was founded in 2016. It employs 1 to 10 people.
Where is Genspeed Biotech based?
Genspeed Biotech is headquartered in Rainbach, Austria, in the Europe region.
How does Genspeed Biotech make money?
Three revenue lines are on record. Diagnostic Test Kits Sales are the primary driver. The others are OEM Platform Licensing and GENSPEED R2 Instrument Sales.
Who are Genspeed Biotech's main competitors?
Direct peers on record are Eurolyser Diagnostica, EKF Diagnostics, Abionic and Response Biomedical. Broad incumbents are QuidelOrtho, Siemens Healthineers POC, Sekisui Diagnostics and Abbott Point of Care. Meso Scale Diagnostics is listed as an others. QuantuMDx is listed as an emerging player.
Does Genspeed Biotech have an API?
No public API is recorded for Genspeed Biotech.
What industry is Genspeed Biotech in?
Genspeed Biotech's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 325413 and its SIC code is 2835.